SCHEMBL2806200

SCHEMBL2806200

Oc1cccc(C#Cc2cccnc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.50
GRM5 P41594 4/20 0.50
ERN1 O75460 1/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2D6 P10635 3/20 0.49
CYP2E1 P05181 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP1A2 P05177 2/20 0.47
CYP2C8 P10632 1/20 0.47
CHRNB2 P17787 2/20 0.46
CHRNA4 P43681 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
FFAR1 O14842 1/20 0.45
MAPT P10636 1/20 0.45
HAO1 Q9UJM8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30963914 1.00 CYP2A6 (0.50) CYP2A6GRM5ERN1CYP2C9CYP2B6
SCHEMBL29793188 0.85 CYP2A6 (0.50) CYP2A6GRM5ERN1CYP2C9CYP2B6
SCHEMBL3796332 0.82 CYP2A6 (0.67) CYP2A6GRM5CYP2C9CYP2B6CYP2C19
SCHEMBL718295 0.82 CA12 (0.60) GRM5CYP2C9CYP3A4CA12CA1
SCHEMBL27952686 0.81 CA12 (0.53) GRM5CYP3A4CA12CA1CA2
SCHEMBL1477031 0.78 GRM5 (0.50) CYP2A6GRM5CYP2C9CYP2B6CYP2C19
SCHEMBL30669242 0.78 GRM5 (0.50) CYP2A6GRM5CYP2C9CYP2B6CYP2C19
SCHEMBL1477185 0.78 GRM5 (0.50) CYP2A6GRM5CYP2C9CYP2B6CYP2C19
SCHEMBL2806708 0.78 MEN1 (0.55) CYP2A6GRM5CYP2C9CYP2B6CYP2C19
SCHEMBL31673182 0.78 GRM5 (0.71) CYP2A6GRM5CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103664637-A Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC 2014-03-26 CN claimed
CN-105541769-A Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC 2016-05-04 CN disclosed
CN-103664637-B Be used for the treatment of ophthalmic diseases and disorderly alkynyl phenyl derivative compounds ACUCELA INC. (US) 2016-02-03 CN disclosed
CN-103664637-A Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC 2014-03-26 CN disclosed
US-20100286353-A1 ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF FUJIFILM CORPORATION (JP) 2010-11-11 US disclosed
US-20100240908-A1 ACETYLENE COMPOUND FUJIFILM CORPORATION (JP) 2010-09-23 US disclosed
EP-2202221-A1 ACETYLENE COMPOUND Fujifilm Corporation (JP) 2010-06-30 EP disclosed
EP-2202220-A1 ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF Fujifilm Corporation (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240908-A1 ACETYLENE COMPOUND NAT1, KATNA1, KAT2B CYP2A6 2596/4885GRM5 2797/4885ERN1 1196/4885
US-20100286353-A1 ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF KAT8, HDAC10, SSRP1 CYP2A6 4283/4885GRM5 3664/4885ERN1 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.